Profound Medical Corp. (TSE:PRN) Director Purchases C$143,319.75 in Stock

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. purchased 14,200 shares of the business’s stock in a transaction dated Friday, March 14th. The stock was bought at an average price of C$10.09 per share, for a total transaction of C$143,319.75.

Profound Medical Stock Performance

Shares of PRN opened at C$10.03 on Thursday. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05. The firm has a market cap of C$211.35 million, a PE ratio of -5.21 and a beta of 0.81. The stock has a fifty day moving average price of C$9.89 and a 200-day moving average price of C$10.50. Profound Medical Corp. has a 12 month low of C$7.90 and a 12 month high of C$15.75.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.